DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for inherited blood coagulation disorder — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInherited blood coagulation disorder maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inherited blood coagulation disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
coagulation factor XIII A chain (F13A1) — F13A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8CMU · 2.41 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The 2011 study on Iranian women reports that von Willebrand disease, Glanzman thrombasthenia and factor XIII deficiency are the most common inherited coagulation disorders in that population, with a high rate attributed to consanguineous marriage. No drug treatment is tested or discussed; the paper recommends psychological and social support alongside coagulation therapy. No survival or response rates are given.
The 2009 review states that blood coagulation disorders causing bleeding or thrombosis often involve multiple genetic and acquired factors, and that interaction between factors can either attenuate or worsen clinical symptoms. No specific drug is mentioned. The 2020 review notes that congenital and acquired coagulation disorders remain an acute clinical problem and that new diagnostic and correction methods have been developed, but it does not name any drug or report trial results.
The 2021 chapter on acquired disorders states that acquired bleeding disorders occur more frequently than inherited forms and are more common in hospitalised patients. It names disseminated intravascular coagulation as an example but does not test any drug or report outcomes. No drug is mentioned in any of the four abstracts.
What is still missing: any clinical trial testing a drug for inherited blood coagulation disorders, any data on survival or response rates, any patient stratification strategy, and any funding for such trials. The abstracts provide only reviews and a social-support recommendation, not evidence for a drug repurposing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Haemophilia · 2011 · 6 citations
How to deal with medical and social aspects of bleeding disorders – preparing women and the family in developing countries
AbstractThere is a considerable number of women with inherited bleeding disorders in Iran. von Willebrand disease, Glanzman thrombasthenia and factor XIII deficiency are the most common coagulation disorders. The main cause of this high rate of coagulation disorders is attributed to a high rate of consanguineous marriages in Iran. Medical care continues to improve for individuals affected with coagulation disorders in Iran. However, these disorders continue to have a significant impact on the affected Iranian women. As a result of the hereditary nature of these disorders, the impact extends to the psychosocial dimension of the lives of the women. Therefore it is recommended that women with coagulation disorders are provided with psychological and social support along with coagulation therapy.
Clinical Chemistry and Laboratory Medicine (CCLM) · 2009 · 5 citations
Multiple gene interaction and modulation of hemostatic balance
AbstractRecent progress in the understanding of the pathophysiology of hemostasis has established that blood coagulation disorders causing bleeding or thrombosis often indicate a multi-casual nature in which the interaction between genetic and acquired factors plays a major mechanistic role. The interaction of two or more factors may attenuate clinical symptoms. However, a synergic worsening may also occur, resulting in a higher risk than expected from the combination of the separate effects. The role of genetic factors on the modulation of the phenotypic expression of coagulation disorders will be addressed in this review, with particular emphasis on the underlying pathogenic mechanisms and clinical implications.
Pediatric Hematology/Oncology and Immunopathology · 2020 · 3 citations · open access
Current trends in blood coagulation studies
AbstractBlood coagulation occurs in flow or stasis conditions, it involves components of cell hemostasis and enzymatic cascades of reactions; it serves to stop bleeding yet it can lead to life-threatening blood thrombi. Despite the fact that a complete list of coagulation proteins was well known for decades, in recent years numerous facts has accumulated about its structure and regulation. All that has led to the creation of new methods for diagnosing of blood coagulation disorders and methods for their correction. Congenital and acquired coagulation disorders are still an acute clinical problem. This review shows modern ideas about the structure and functioning of the blood coagulation system in various conditions.
Oxford University Press eBooks · 2021 · 2 citations
Acquired disorders of haemostasis
AbstractThis chapter covers non-hereditary causes of bleeding and thrombosis, which are referred to as acquired disorders that arise as a consequence of another primary disorder that may be hereditary or acquired. It names a number of acquired haemostatic disorders and describes their causes. It also discusses how acquired disorders of haemostasis can affect routine coagulation screening tests and how routine and specialist haemostasis assays can be employed to diagnose acquired disorders of haemostasis. The chapter explains that acquired bleeding disorders occur more frequently than inherited forms and are more common in hospitalized patients. It mentions disseminated intravascular coagulation (DIC), which results from excessive activation of coagulation exacerbated by loss of regulatory and localization mechanisms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
